Abstract 4386: HJ-099, a novel, orally bioavailable pan-KRAS (ON) non-covalent inhibitor, demonstrates significant antitumor activity in multiple preclinical models with KRAS mutations

Authors: Xiangyu Yang, Fengtian Du, Na Guo, Huiqiao Ling, Shuai Luo, Xiaorong Yu, Qingqing Qian, Ruisi Wu, Jingyu Tian, Jianxin Ji, Li Zhang

Published: 2025-04-21

DOI: 10.1158/1538-7445.am2025-4386

Source: Full article